Mualliflar

  • Аляви А.Л., Юнусова Л.И., Туляганова Д.К., Раджабова Д.И., Хан Т.А., Иманкулова Дж.А.

##semicolon##

ишемическая болезнь сердца, сахарный диабет 2 типа, липидный обмен, углеводный обмен, резидуальный риск, реваскуляризация миокарда.

##submission.citations##

American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl.1):S1–S154.

Anderson TJ, Charbonneau F, Title LM, et al. Microvascular function predicts cardiovascular events in primary prevention. Circulation. 2011;123:163–169.

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380:11–22.

Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review. Cardiovasc Diabetol. 2018; 17:83.

International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels: IDF; 2022.

Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–638.

Koskinas KC, Siontis GCM, Piccolo R, et al. Impact of diabetes on outcomes after revascularization with drug-eluting stents. J Am Coll Cardiol. 2020;75 (21):2427–2438.

Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020; 41:111–188.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375:1834–1844

Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation. 2018;137(13):1391–1406.

Nicholls SJ, Puri R, Anderson T, et al. Residual cardiovascular risk: Clinical and mechanistic insights. Eur Heart J. 2020;41(25):2589–2602.

Packer M. Heart failure: The most important, preventable, and treatable cardiovascular complication of type 2 diabetes. Diabetes Care. 2020;43(7):1530–1532.

Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Eur Heart J. 2013;34(31):2436–2446.

Taskinen MR, Borén J. Residual risk and atherogenic dyslipidemia in statin-treated patients with type 2 diabetes. Diabetes Care. 2015;38(1):139–146.

Verges B. Pathophysiology of diabetic dysli-pidemia: where are we? Diabetologia. 2015;58(5):886–899.

Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. J Am Coll Cardiol. 2010; 55 (13):1318–1327.

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347–357.

World Health Organization. Cardiovascular diseases (CVDs). WHO Fact sheet, 2022.